News Hub | News Direct

Keeping Cognitive Health Top of Mind

YourUpdateTV

Cognitive health is an essential component of our overall well-being as we age.1 Recently, Dr. Jeffery Blumberg participated in a nationwide satellite media tour to discuss new study results released on the large-scale, clinical trial COSMOS-Mind, which suggests that those who took Centrum Silver demonstrated improvement in cognitive function in comparison to the placebo. A video accompanying this announcement is available at: Finding a way to support cognitive function in older adults is an important public health issue, as roughly two out of every three Americans experience some level of cognitive impairment around the age of 70.2 Centrum, a leader in multivitamins for nearly 50 years, has a long history of supporting research to advance the science on benefits of vitamin/mineral supplementation. It is the most clinically studied multivitamin brand in the world. In continuing with this strong heritage, Centrum Silver product, placebo, and packaging was provided in support of the Cocoa Supplement and Multivitamin Outcomes Study (COSMOS) trial. Centrum Silver was specifically selected for the COSMOS-Mind trial which investigated the effects of multivitamin and cocoa flavonoid consumption on cognitive functioning in 2,262 women and men, 65 years and older, over the course of three years. The COSMOS-Mind team tested each participant’s cognitive function via baseline and annual cognitive assessments.3 The results of the COSMO-Mind Study show that an intervention as simple as taking Centrum Silver could help support cognitive function, memory, and executive function in older adults.4* Participants who took Centrum Silver showed significant improvement in their episodic memory – the memory that is tied to specific events or experiences, as well as their executive function as compared to placebo.5 A detailed report on the COSMOS-Mind Study published in Alzheimer & Dementia Journal can be found here. For more information on Centrum and Centrum Silver, please visit Centrum.com. * This product has not been evaluated by the Food and Drug Administration. This Product is not intended to diagnose, treat, cure, or prevent any disease. About Dr. Jeffery Blumberg Health & Nutrition expert Dr. Jeffrey Blumberg is an active professor emeritus in Friedman School of Nutrition Science and Policy at Tufts University, whose experience leans into the promotion of cognitive health. Dr. Blumberg is available to discuss the importance of overall health and nutrition with an emphasis on the recent COSMOS-Mind findings and the potential benefits of taking multivitamins like Centrum Silver. About Centrum Centrum has spent decades listening to the human body and learning about what it needs to thrive. The brand offers nutritional products that work in harmony with your body and help you respond to its unique needs. Innovation and research remain to be the building blocks of the brand’s foundation. For more information about Centrum, please visit www.centrum.com. About Haleon US Haleon is a leading global consumer health company with a portfolio of brands trusted daily by millions of people. In the United States, the organization employs more than 4,700 people who are united by Haleon’s powerful purpose to deliver better everyday health with humanity. Haleon’s products span five categories: Oral Health, Pain Relief, Respiratory Health, Digestive Health, and Wellness. Built on scientific expertise, innovation, and deep human understanding, Haleon’s brands include Abreva, Advil, Benefiber, Centrum, ChapStick®, Emergen-C, Excedrin, Flonase, Gas-X, Natean, Nexium, Nicorette, Parodontax, Polident, Preparation H, Pronamel, Sensodyne, Robitussin, Theraflu, TUMS, Voltaren, and more. For more information on Haleon and its brands, please visit www.haleon.com or contact USMediaRelations@haleon.com. 1 Cognitive impairment in the U.S.: Lifetime risk, age at onset, and years impaired. PMC (nih.gov). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7153285/. Accessed 3/24/22. 1 Cocoa Supplement and Multivitamin Outcomes Study for the Mind. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/study/NCT03035201. Accessed 3/24/22. 1 Executive Functions | Memory and Aging Center. https://memory.ucsf.edu/symptoms/executive-functions. Accessed 3/24/22. 1 Executive Functions | Memory and Aging Center. https://memory.ucsf.edu/symptoms/executive-functions. Accessed 3/24/22. 1 Perceptions of Cognitive Health Factsheet. CDC. https://www.cdc.gov/aging/pdf/perceptions_of_cog_hlth_factsheet.pdf. Accessed 3/24/22. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

October 27, 2022 11:58 AM Eastern Daylight Time

Video

A New BioTech Research Race Is Focused On Improving Life For MS Patients

Pasithea Therapeutics Corp.

Learn More about Pasithea Therapeutics by gaining access to the latest research report When the world is focused on a global pandemic no one saw coming four years ago, the attention given to escalating diseases with no known cure can be hidden from the public consciousness. This is perhaps the case with multiple sclerosis (MS), an immune-mediated disease affecting the central nervous system, which according to the National Institutes of Health, continues to grow. The estimated number of people with MS worldwide increased from ~2.1 million in 2013 to 2.8 million in 2020, with the global prevalence at almost 36 per 100,000 people. The increased number of cases has subsequently increased the demand for effective diagnosis and treatment of multiple sclerosis. A recent Fortune Business Insights report said the global multiple sclerosis drugs market size was valued at $23.68 billion in 2021 and is projected to grow to $33.17 billion by 2029. Rising MS Numbers Spur Increased Research As companies launch new products and research, government initiatives are projected to improve the accessibility of care and treatment. The rising MS numbers are believed to be the primary catalyst in market expansion. Active biotech companies in the MS market today include Pasithea Therapeutics Corp. (NASDAQ: KTTA ), BioNTech SE (NASDAQ: BNTX ) and SIGA Technologies Inc. (NASDAQ: SIGA ) and Moderna Inc. (NASDAQ: MRNA), among others. Some are finding new research showing that an mRNA vaccine might also work in multiple sclerosis (MS). BioNTech and scientists at the Johannes Gutenberg University of Mainz hypothesized that an mRNA vaccine could work in a targeted fashion to help the immune system tolerate specific MS-related proteins without compromising normal immune function. The BioNTech team developed an mRNA candidate wrapping the genetic information coding for MS-causing self-antigens in fatty substances. A similar lipid nanoparticle is used in Comirnaty to protect the COVID-19 mRNA material until it reaches target cells, where it produces the antigen protein. The results were published in the journal Science. Pasithea Reports Progress In Pursuit Of MS Vaccine Development Pasithea, a biotechnology company focused on discovering, researching and developing new and effective treatments for psychiatric and neurological disorders, recently announced positive results from a preliminary preclinical proof-of-concept study of PAS002, its tolerizing vaccine program in MS. The Pasithea vaccine promotes immune tolerance to a specific myelin protein, reducing the severity of relapses and helping the test animals gain weight, indicating a better overall health status. “Although early-stage data, we’re thrilled with the results of this study and the strong preclinical efficacy data of our tolerizing approach,” Pasithea CEO Dr. Tiago Reis Marques said. While regular vaccines usually are designed to train the body to develop an immune response against a particular pathogen, tolerizing vaccines essentially do the opposite, acting as a “reverse vaccine.” Those vaccines train the immune system to tolerate a molecule, suppressing an unwanted immune response against it. Pasithea hopes that helping the immune system accept GlialCAM, PAS002 will prevent the attacks that cause myelin loss in the brain and spinal cord, thereby reducing disease severity and MS relapses. Another recent article in Science showed published research that scientists have discovered about the risk of an individual contracting MS. The study showed that MS increases 32-fold after a person is infected with the Epstein-Barr virus. However, the risk of developing the condition does not increase when other viruses infect the patient. The scientists also tested MS biomarkers showing neurodegeneration. There are currently 15 vaccines actively under development for the Epstein-Barr virus, most of which are in discovery or preclinical stages. The Modified vaccinia Ankara (MVA) vaccine under development by the Chinese University of Hong Kong is in Phase II. It uses the same technology as AstraZeneca plc (NASDAQ: AZN) and Johnson & Johnson (NYSE: JNJ) on their COVID-19 vaccines. The most prominent company involved, Moderna, has started testing the vaccine mRNA-1189, which uses mRNA technology, in Phase I studies. If successful, the vaccine could be one of the first on the market for the Epstein-Barr virus. Though the Moderna vaccine does not indicate MS, it could eventually help with disease prevention. For more information on Pasithea Technologies, visit pasithea.com. Pasithea Therapeutics Corporation is a biotechnology company focused on the discovery, research and development of new and effective treatments for central nervous system (CNS) disorders. With an experienced team of experts in the fields of neuroscience and psychopharmacology, Pasithea is developing new molecular entities for the treatment of psychiatric and neurological disorders, including Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS). Pasithea addresses the needs of patients currently suffering with mental illness by providing access to IV ketamine infusions both in clinics and in-home settings. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details TraDigital IR- Camille Baptiste camille@tradigitalir.com Company Website https://www.pasithea.com/

October 27, 2022 09:50 AM Eastern Daylight Time

This Company Is Looking For A Monkeypox Drug As City Investigates Deaths

NanoViricides, Inc.

Learn more about NanoViricides, Inc. by gaining access to the latest research report New York City is investigating the cause of death for two people who died after contracting monkeypox. Though both of the deceased had higher fatality risk because of underlying conditions, concerns about the virus and its transmissibility have been growing. The current number of monkeypox cases in the city stands at 3,695. Overall, there are just over 28,000 cases of monkeypox across America. Tackling monkeypox head-on, NanoViricides Inc. (NYSE: NNVC) is launching a monkeypox initiative. NanoViricides is a biotech company seeking treatments in the antiviral and nanomedicine space, developing a variety of drugs for diseases like COVID-19, shingles, HIV, swine flu and others. It is now hopeful as it begins developing a treatment to tackle monkeypox. Working Hard To Find A Cure NanoViricides isn’t monkeying around as it begins developing a drug for the disease. It believes itself to be well positioned in the biotech field to find a treatment. It is one of the few biopharma companies to have its own current good manufacturing practice (cGMP)-compliant manufacturing facility, meaning it follows the stringent Food and Drug Administration (FDA) regulations in all its novel drug development work. Plus, NanoViricides has a large library of broad-spectrum antiviral nanoviricides from which it can draw to test on pox viruses. It has the resources necessary to expedite the process of finding a proper treatment. It hopes to develop a systemic treatment — one that is both oral and injectable — and may also work on a skin cream to treat the rash associated with monkeypox. The quicker these treatments can be rolled out, the sooner they can help those infected with the disease. New York City’s health department responded to the two recent deaths with a statement: “We are deeply saddened by the two reported deaths and our hearts go out to the individuals' loved ones and community. Every effort will be made to prevent additional suffering from this virus through continued community engagement, information-sharing and vaccination.” NanoViricides believes it will be able to develop a drug in response to monkeypox in relatively quick order. Meanwhile, the company’s priority remains the development of its drug candidate NV-CoV-2, for treating COVID-19. To learn more about NanoViricides, visit its website. About NanoViricides NanoViricides, Inc. (the "Company") (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Our lead drug candidate is NV-HHV-101 with its first indication as dermal topical cream for the treatment of shingles rash. In addition, we are developing a clinical candidate for the treatment of COVID-19 disease caused by SARS-CoV-2 coronavirus. The Company cannot project an exact date for filing an IND for this drug because of its dependence on a number of external collaborators and consultants.The Company is now working on tasks for completing an IND application. The Company is currently pursuing two separate drug candidates for the treatment of COVID-19 patients. NV-CoV-2 is our nanoviricide drug candidate that does not encapsulate Remdesivir. NV-CoV-2-R is our other drug candidate that is made up of NV-CoV-2 with Remdesivir encapsulated in it. The Company believes that since Remdesivir is already US FDA approved, our drug candidate encapsulating Remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.The Company intends to re-engage into an IND application to the US FDA for NV-HHV-101 drug candidate for the treatment of shingles once its COVID-19 project moves into clinical trials, based on resources availability. The NV-HHV-101 program was slowed down because of the effects of recent COVID-19 restrictions, and re-prioritization for COVID-19 drug development work.The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for poxviruses if the initial research is successful. The Company's technology is based on broad, exclusive, sub-licensable, field licenses to drugs developed in these areas from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005. This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Contact Details NanoViricides, Inc. +1 203-937-6137 info@nanoviricides.com Company Website http://www.nanoviricides.com

October 27, 2022 09:25 AM Eastern Daylight Time

Elsevier and the American College of Medical Genetics and Genomics Announce the Forthcoming Launch of Genetics in Medicine Open

Elsevier

The American College of Medical Genetics and Genomics (ACMG), the only nationally recognized US medical professional organization solely dedicated to improving health through the practice of medical genetics and genomics, and Elsevier, a global leader in research publishing and information analytics, are delighted to announce the January 2023 launch of a new gold open access, online only journal: Genetics in Medicine Open ( GIM Open ), an Official Journal of the ACMG. GIM Open will complement ACMG’s flagship journal Genetics in Medicine ( GIM ), also published by Elsevier, and is designed to meet the evolving needs of the global medical genetics and genomics community and expand its open access publishing options. Published under Creative Commons license, all GIM Open articles will be immediately, permanently, and openly available online for readers to view, download, share, and reuse. This will enable authors to more easily comply with funder and institutional mandates, even as requirements continue to evolve. ACMG’s decision to expand the breadth of its openly available content directly supports its mission to improve personal and public health through the clinical and laboratory practice of medical genetics; advocacy, education, and clinical research programs; and the safe and effective integration of genetics and genomics into all of medicine and healthcare. “I am excited about our new gold open access journal that will be available to anyone, anytime, anywhere in the world independent of financial resources or library access. GIM Open will be an international journal with a focus on medical genetics and genomic medicine including all aspects of therapy,” noted ACMG retiring Chief Executive Officer Maximilian Muenke, MD, FACMG, who led the development of the new journal. “It will be a trail blazer for diversity, equity, and inclusion from a double anonymous review process of manuscripts, to the Editor-in-Chief and an editorial board that truly reflects our society in the United States and around the world. We are fortunate to work with our colleagues Robert D. Steiner, MD, FAAP, FACMG, and Jan Higgins, PhD, ELS, from GIM and our publisher Elsevier on the start of this new venture. As a medical geneticist who thinks that genomic medicine is the present and future of medicine, GIM Open will educate healthcare professionals to contribute to optimal patient care everywhere.” GIM Open’s eminent international editorial board will be led by Editor-in-Chief Bo Yuan, PhD, FACMG, Baylor College of Medicine, an internationally recognized expert in the field. “I am tremendously honored and excited to serve as the founding editor of this new journal that will actively support open science for the medical, scientific and research professionals in a broad range of specialties who comprise our ACMG community,” said Dr. Yuan. “Collectively, members of the editorial board and I are dedicated to the rapid dissemination of high quality, authoritative and cutting-edge medical genetic knowledge both within and beyond the genetics community with the ultimate goal of improving patient outcomes.” Louise Curtis, Senior Vice President, Life Sciences and Social Sciences, Elsevier, commented, “We are extremely pleased to expand our publishing portfolio with ACMG, building on our collaborative partnership with this prestigious society that began in 2022 with publication of GIM. Launching GIM Open strongly aligns with our mission to help researchers and healthcare professionals advance science and improve health outcomes for the benefit of society, and we share the commitment to inclusion and diversity at the heart of this exciting new venture.” GIM Open manuscript processing will include rigorous double anonymous peer review, a rapid submission to publication decision turnaround time, and an expedited publication timeline. Detailed instructions for authors and information regarding open access and publishing fees can be found here. Manuscript submission will open as of October 25, 2022. Papers submitted to GIM may be considered for publication in GIM Open if deemed more appropriate for that journal. It is Elsevier’s intention to submit GIM Open for inclusion in the major abstracting and indexing services at the earliest opportunity. As one of the fastest-growing open access publishers in the world, nearly all of Elsevier's 2,700 journals enable open access publishing, including 600 fully open access journals. In 2021, Elsevier published 119,000 gold or pay-to-publish open access articles, an increase of more than 46% over 2020, making Elsevier one of the largest open access publishers in the world. Notes for editors About Genetics in Medicine Open ( GIM Open ) Genetics in Medicine Open ( GIM Open ) is an open access journal with a broad focus on medical genetics and genomic medicine including all aspects of therapy. It will have a strong emphasis on diversity, equity, and inclusion and will have a double anonymous review process for submitted manuscripts. Positioned as an official journal of the American College of Medical Genetics and Genomics (ACMG) and the companion journal of Genetics in Medicine, GIM Open aims to be an international journal publishing research studies that advance the knowledge, understanding, and practice of medical genetics and genomic medicine for all continents. GIM Open welcomes submissions of Original Research, Reviews, Commentaries and Brief Reports in the areas of clinical genetics, cytogenetics, molecular genetics, biochemical genetics, reproductive medicine, cancer genetics, pharmacogenomics, clinical trials, population genetics, public health, genome-wide association studies, polygenic risk, bioinformatics, methodologies, clinical implementation, ELSI (ethical, legal and social issues), genetic counseling, and practical standards and guidelines. Manuscripts reporting animal models providing clinically relevant insights into human disease mechanisms and potential therapeutics are also welcome. Manuscripts of candidate disease gene discoveries based on a small cohort size but solidified by a high standard of scientific rigor, validity and reproducibility may be considered. Rare case reports may be considered if they fill a knowledge gap in populations underrepresented in genetics research or experiencing health disparities, or inform exceptionally significant actionability in diagnosis, prognosis, and therapeutics. GIM Open promotes studies that include diverse especially under-represented populations. www.gimopen.org About Elsevier and society partnerships Elsevier has long-standing partnerships with over 600 learned societies worldwide, helping them to realize their missions and inspire and support their communities. We pride ourselves on consistently delivering outstanding publishing outcomes through strategic insight, reliable finances, global dissemination, embracing open science and open access, and championing the needs of the communities we jointly serve. www.elsevier.com/societies About American College of Medical Genetics and Genomics (ACMG) Founded in 1991, the American College of Medical Genetics and Genomics (ACMG) is the only nationally recognized medical professional organization solely dedicated to improving health through the practice of medical genetics and genomics, and the only medical specialty society in the US that represents the full spectrum of medical genetics disciplines in a single organization. The ACMG is the largest membership organization specifically for medical geneticists, providing education, resources and a voice for nearly 2,500 clinical and laboratory geneticists, genetic counselors and other healthcare professionals, nearly 80 percent of whom are board certified in the medical genetics specialties. ACMG’s mission is to improve health through the clinical and laboratory practice of medical genetics as well as through advocacy, education and clinical research, and to guide the safe and effective integration of genetics and genomics into all of medicine and healthcare, resulting in improved personal and public health. www.acmg.net About the Editor-in-Chief Bo Yuan, PhD, FACMG is an Associate Professor of the Human Genome Sequencing Center (HGSC) and the Department of Molecular and Human Genetics at Baylor College of Medicine (BCM). He is also a Division Director of the Clinical Laboratories of HGSC. After receiving his Bachelor’s degree from Nankai University in China, he came to the United States and completed his PhD training in molecular and human genetics at BCM. He then received the American Board of Medical Genetics and Genomics (ABMGG) fellowship at BCM and was subsequently board-certified in Clinical Molecular Genetics and Clinical Cytogenetics. Dr. Yuan is an active laboratory geneticist and academic researcher with interest in characterizing new mechanisms of human genetic disorders, investigating, developing and implementing tools to improve molecular diagnostics and genomic data interpretation, and enhancing the visibility of genomic medicine in clinical care. He has authored and co-authored more than 60 peer-reviewed publications and book chapters. Dr. Yuan is a Fellow of the American College of Medical Genetics and Genomics (ACMG). He is also a contributing member of other professional communities, including the American Society of Human Genetics (ASHG), ClinGen Variant Curation Expert Panel, and ACMG evidence-based guideline (EBG) workgroup. He has also been a longtime reviewer for a number of journals. About Elsevier As a global leader in information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making for customers across the global research and health ecosystems. In everything we publish, we uphold the highest standards of quality and integrity. We bring that same rigor to our information analytics solutions for researchers, health professionals, institutions and funders. Elsevier employs 8,700 people worldwide. We have supported the work of our research and health partners for more than 140 years. Growing from our roots in publishing, we offer knowledge and valuable analytics that help our users make breakthroughs and drive societal progress. Digital solutions such as ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath support strategic research management, R&D performance, clinical decision support, and health education. Researchers and healthcare professionals rely on our over 2,700 digitized journals, including The Lancet and Cell; our over 43,000 eBook titles; and our iconic reference works, such as Gray's Anatomy. With the Elsevier Foundation and our external Inclusion & Diversity Advisory Board, we work in partnership with diverse stakeholders to advance inclusion and diversity in science, research and healthcare in developing countries and around the world. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com Contact Details Elsevier Kiran Dhaliwal - Global Press & Communications Manager newsroom@elsevier.com American College of Medical Genetics and Genomics Kathy Moran - Senior Director, Communications and Public Relations kmoran@acmg.net Company Website https://www.elsevier.com/

October 27, 2022 09:00 AM Eastern Daylight Time

Image

Software Effective Solutions Subsidiary MEDCANA (OTC: SFJW) Announces Successful Launch of Test Greenhouses for Microclimates and Genetics with Colombia Partner Firms

Software Effective Solutions Corp.

Software Effective Solutions Corporation (OTC: SFWJ) (“The Company”, “SFWJ”) subsidiary Medcana is pleased to announce the successful launch of test greenhouses for microclimates and genetics with five partner firms in Colombia, South America. With significantly better economics than the US and Canada, a central location for exportation to major markets, and prime cultivation characteristics, Colombia is believed by many to have significant cultivation advantages over other regions around the world. According to Arcview Market Research, the cost to cultivate cannabis in Colombia is 60X less expensive than in Canada and 30X less than in the U.S. José Gabriel Diaz, The Company’s CEO, states, “We have begun simultaneous testing in all five partner companies. The goal is to test microclimate, genetics, local pests, and any other factors that may affect the final design and selection of genetics. The plan is to have our partners run tests with desired strands and analyze initial results.” “As well, the greenhouses are a very small fraction of the planned builds but allow us to test conditions and begin micro-testing genetics. The plan is to run one 90-day cycle and make sure the test parameters yield the expected results.” Medcana partners will also be running tests in native soil for near-term open-air cultivation possibilities for the Company. For now, the greenhouses give Medcana and partners a controlled environment to ensure native soil results are accurate. Software Effective Solutions/MedCana is a global infrastructure and holding company in the cannabis industry. The recent acquisition of a software company expanded the offering to provide traceability from plant to product. MedCana's initial focus is on developing clients and companies in Latin America, with an initial focus on Colombia and partnerships with laboratories, research facilities, and hospitals throughout the world. “In order to build something right and well, we must go slow, analyze, and test all variables. We have done a phenomenal job with the initial analysis for infrastructure, with geological, hydrological, and environmental factors. Now we want to test further. All things matter, wind currents, small changes in humidity, soil, pests, we want to make sure all is analyzed and tested,” adds Diaz. MedCana aims to build its Partner companies into one of the most advanced Cannabinoid production and processing organizations globally SAFE HARBOR STATEMENT This press release contains forward-looking statements that can be identified by terminology such as "believes," "expects," "potential," "plans," "suggests," "may," "should," "could," "intends," or similar expressions. Many forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results implied by such statements. These factors include, but are not limited to, our ability to continue to enhance our products and systems to address industry changes, our ability to expand our customer base and retain existing customers, our ability to effectively compete in our market segment, the lack of public information on our company, our ability to raise sufficient capital to fund our business, operations, our ability to continue as a going concern, and a limited public market for our common stock, among other risks. Many factors are difficult to predict accurately and are generally beyond the company's control. Forward-looking statements speak only as to the date they are made, and we do not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made. Signed. /s/ Jose Gabriel Diaz, CEO www.medcana.net info@medcana.co Contact Details Chris Greta +1 512-587-5175 chris@chrisgreta.com Company Website https://www.medcana.net/

October 27, 2022 08:30 AM Eastern Daylight Time

Are You Getting Enough Physical Activity?

YourUpdateTV

Despite a wealth of research showing how even moderate amounts of physical activity can lead to better health and longer life, millions of Americans don’t get enough of it. Recently, Carrie Pagliano, PT, DPT, participated in a nationwide satellite media tour to discuss the importance of staying active and how physical therapy can help. A video accompanying this announcement is available at: https://youtu.be/RlbXcIoVJ74 Earlier this year, the Centers for Disease Control and Prevention released results of a study showing that more than 1 in 5 adults in the United States are inactive. Given that lack of physical activity is associated with pain and stiffness and higher rates of chronic conditions — such as heart disease, obesity, diabetes, and some cancers — it’s critical that people embrace movement and seek out physical activity. A great first step is working with a health care provider, like a physical therapist, to discuss your physical activity options. APTA advocates in support of programs that increase physical activity, exercise among all individuals, and encourages active transportation. Physical therapists are uniquely qualified to help people get and stay moving. They are movement experts who improve quality of life through hands-on care, patient education, and prescribed movement. Physical therapists work in various settings with all patient populations from birth to older adults; they identify, diagnose, and treat movement problems in people of all ages and abilities. Visit ChoosePT.com for more information and to find a physical therapist in your area. Carrie Pagliano, PT, DPT, is a physical therapist and has been a dynamic leader in clinical care and education in the areas of women’s/pelvic health and orthopedics for more than 20 years. She is founder and owner of Carrie Pagliano PT, LLC, in Virginia, and an adjunct professor at Marymount and Lynchburg universities. She received her master’s degree in physical therapy from the University of the Sciences and doctor of physical therapy from the University of St. Augustine for Health Sciences. She is a board-certified clinical specialist in orthopaedics and women’s health, holds manual therapy certification, and an advocate for women and mothers in leadership in the physical therapy profession. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

October 26, 2022 03:03 PM Eastern Daylight Time

Video

Charitable Foundation Awards $290,000 in Support of Vulnerable Populations Nationally

Sevita

The MENTOR Network Charitable Foundation, Sevita ’s private foundation, a leading national provider of community-based health care and support services, announced that it has awarded grants totaling $290,000 to eight organizations in its fiscal year 2022 grant cycle. The organizations awarded support some of our nation’s most vulnerable populations, including individuals with intellectual and developmental disabilities, those with brain and spinal cord injuries, youth facing emotional, behavioral, and other challenges, and their families and caregivers. “We are proud to support the work of these truly amazing organizations,” said Whitney Shufelt, Executive Director of the Foundation. “When we began this grant program 15 years ago, we did so with the intent of forming lasting partnerships, investing in community organizations, and driving forward real change. It has been wonderful to see these efforts come to fruition and continue to grow.” Grant recipients include: Special Olympics: supporting the Healthy Communities US-based inclusive health program and its digitization efforts (national) National Inclusion Project: second year online Inclusive Recreation Specialist Course for recreation and special education professionals (national) RespectAbility: funding for two apprentices to complete the National Leadership Program for adults with disabilities (national) Oak Hill Centers for Relationship and Sexual Education: supporting the launch of a crisis fund for victims with communication challenges and first responder training of augmentative alternative communication (national) Rise Above Foundation: funding for extracurricular, educational, and fun experiences for youth engaged in the child welfare system (Massachusetts) United Cerebral Palsy: scholarships for clinicians from underserved communities and non-MD and non-DO health professionals to attend Cerebral Palsy conferences focused on early detection and early intervention (national) Kidpower International: supporting the Trauma to Thriving social emotional health program for vulnerable children and adults with IDD (national) Autism Empowerment Network: Readiness and autism employment resource center for workers with autism (Pennsylvania) Grants are awarded to 501(c)(3) organizations whose values align with Sevita’s core belief that everyone has the right to live well. These organizations are change agents within health care and human services and are delivering innovative care, developing new ideas and models to improve access to quality health care, and creating opportunities for individuals to live a full, more independent life. “The ongoing efforts of these eight organizations have provided support, resources, and a voice for individuals who are often overlooked,” said William McKinney, president and chair of The MENTOR Network Charitable Foundation. “In addition, they have evolved and adapted as the landscape in which we work and live continues to shift. Their impact is tangible, and we are happy to be able to support it. We thank them for their dedication and shared commitment to the communities we serve.” Since its establishment in 2007, the MENTOR Network Charitable Foundation has awarded more than $3 million to over 300 organizations across 30+ states. In addition to these grant awards, the MENTOR Network Charitable Foundation will announce its Community Champions grants in November. The Community Champions grants celebrate Sevita team members who have dedicated their time, talents, and energy to local charities. Individuals will receive recognition for their dedication and their chosen nonprofit will receive a grant from the Foundation. For more information, visit networkcharitablefoundation.org/. Sevita is a leading provider of community-based specialized health care. We believe that everyone deserves to live a full, more independent life. We provide people with quality services and individualized supports that lead to growth and independence, despite the physical, intellectual, or behavioral challenges they face. We've made this our mission for more than 50 years. Today our team members continue to innovate and enhance care for the 55,000 individuals we serve. sevitahealth.com Contact Details Melissa Patricio media@sevitahealth.com Company Website https://sevitahealth.com/

October 26, 2022 01:00 PM Eastern Daylight Time

AmeriLife Partners with Health Resource Advisors

AmeriLife

AmeriLife Group, LLC (“AmeriLife”), a national leader in developing, marketing, and distributing life and health insurance, annuities and retirement planning solutions, announced today that it has partnered with Health Resource Advisors, a Baltimore-based field marketing organization (FMO). Health Resource Advisors specializes in supporting independent, licensed Medicare agents with proprietary tools, training and resources to cultivate meaningful client relationships, grow their books of business, and maximize their potential. Per the agreement, terms of the deal were not disclosed. "Health Resource Advisors has always been – and will continue to be – focused on its most important asset: our agents,” said Andrew Rosenberg, president of Health Resource Advisors. “With AmeriLife and its industry-leading resources at our side, we’re excited to create more opportunities for the incredibly talented agents within our community.” Since Health Resource Advisors’ founding in 2007, the firm has grown from a single agent and client to several hundreds of affiliated agents serving thousands of Medicare beneficiaries nationwide. The firm boasts some of the deepest carrier relationships in the markets and communities it serves, and has excelled at identifying and nurturing top producing agents that consistently set industry standards. “Partnering with AmeriLife means gaining an advocate that will champion your growth and the development of your agents,” said Mike Vietri, AmeriLife’s Chief Distribution Officer. “Health Resource Advisors is a fiercely independent firm whose approach and values are perfectly aligned with ours. We’re thrilled to welcome them to the AmeriLife family, and look forward to accelerating their success.” ### About Health Resource Advisors Health Resource Advisors is a field marketing organization (FMO) in Baltimore, Md., specializing in Medicare coverage. The company supports independent insurance agents by providing the tools and resources they need to grow their portfolio and serve their clients better. For more information, visit HealthResourceAdvisors.com. About AmeriLife AmeriLife’s strength is its mission: to provide insurance and retirement solutions to help people live longer, healthier lives. In doing so, AmeriLife has become recognized as the leader in developing, marketing, and distributing life and health insurance, annuities and retirement planning solutions to enhance the lives of pre-retirees and retirees across the United States. For more than 50 years, AmeriLife has partnered with top insurance carriers to provide value and quality to customers served through a distribution network of over 300,000 insurance agents and advisors and more than 100 marketing organizations and insurance agency locations nationwide. For more information, visit AmeriLife.com, and follow AmeriLife on Facebook and LinkedIn. Contact Details Media Jeff Maldonado +1 321-297-1112 jmaldonado@amerilife.com Partnership Inquiries Patrick Nichols +1 727-726-0726 pnichols@amerilife.com Company Website https://amerilife.com/

October 26, 2022 10:00 AM Eastern Daylight Time

Can This Company’s Birth Control Patch Disrupt The Contraceptive Market?

Agile Therapeutics, Inc.

From Evofem Biosciences Inc. ’s (OTCMKTS: EVFM) Phexxi vaginal gel contraceptive to Dare Bioscience Inc. ’s (NASDAQ: DARE) Ovaprene, an investigational hormone-free monthly intravaginal contraceptive, the market is never in short supply of birth control products. While the issue of birth control and abortion can be embroiled in continuous debates and controversies, contraceptives have been known to reduce the rate of unintended pregnancies, the need for unsafe abortions, and HIV transmissions from mothers to newborns. The need is strong - a 2020 report by the World Health Organization (WHO) said that among 1.9 billion reproductive-age women (15 to 49 years) globally in 2019, around 1.1 billion women require family planning and 270 million of those have an unmet need for contraception. Disruptive Contraceptive Patch? The rising number of women with unmet contraceptive drugs and device needs could present unique opportunities for industry players. Agile Therapeutics Inc. ’s (NASDAQ: AGRX) Twirla® (levonorgestrel and ethinyl estradiol) transdermal system could be one innovative product with the potential to disrupt the industry. New Jersey-based Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet needs of today’s women. The company’s product and product candidates are designed to offer women more freedom and flexibility through additional contraceptive options. Agile Therapeutics Chairman and CEO Al Altomari, speaking at the H.C. Wainwright 24th Annual Global Investment Conference in September, revealed that the company is currently focused on the growth of its first Food and Drug Administration (FDA)-approved product Twirla®. Twirla®, the company reports, is the first and only birth control patch delivering a low dose of estrogen. Twirla delivers 30 micrograms (mcg) of estrogen daily, the lowest exposure of estrogen in a transdermal contraceptive option. Unlike most oral contraceptives on the market that women take at least 21 days each month, Twirla® uses just three patches a month. Agile Therapeutics plans to commercialize and upscale Twirla through its business plan — non-retail channel growth driver ( Afaxys GPO ) and retail channel growth drivers (telemedicine providers like Nurx & Twirla’s DTC CTV commercial ). With the growth of Twirla® being the main focus, the company believes that building a U.S. women’s health franchise on the foundation of the patch’s commercial success can enhance value for shareholders. “We have sought out and will continue to explore partnerships and opportunities that leverage our existing infrastructure, including co-promotion and business development opportunities,” Altomari said. Cash On Hand And The Way Forward Agile Therapeutics raised net proceeds of approximately $12.2 million through its at-the-market (ATM) offering in the second quarter of 2022 and $22.2 million in an upsized public offering in July 2022. The company reduced the outstanding principal amount owed to Perceptive Advisors to $3 million with proceeds from ATM. Agile Therapeutics established a new $75 million ATM in August 2022. From the end of the fourth quarter to the end of the second quarter of 2022, the company reduced its quarterly operating expenses (OPEX) from $18.2 million to $11.3 million while still growing Twirla demand by 27%. The company now believes it has sufficient cash on hand to fund operations through the end of 2022. In the second quarter of 2022, Agile Therapeutics realized net product sales revenue of $2.1 million, an increase of 75% compared to the second quarter of 2021 revenue of $1.2 million. Total operating expenses for the second quarter of 2022 were $11.3 million. Non-retail sales primarily associated with the Afaxys partnership are expected to significantly accelerate in the second half of 2022. Non-retail channels experience higher gross-to-net discounting compared to retail channels and therefore the company expects overall gross-to-net discounts to increase as a percentage of gross revenue. Agile Therapeutics intends to use its resources to continue to grow Twirla® and to improve on its performance as it prepares to report third-quarter 2022 financial results and Twirla® growth update in November. One of the Company’s financial goals is to become cash flow positive. “Our focus in 2022 has been on growing Twirla and advancing towards generating positive cash flow,” said Agile Therapeutics Chairman and Chief Executive Officer Al Altomari. “In 2022, we have significantly reduced our operating expenses by redesigning how we work to gain efficiencies and implemented a plan we believe can drive Twirla growth through our Afaxys partnership, connected TV (CTV) campaign, and growing the telemedicine channel. ” Agile Therapeutics is a women's healthcare company dedicated to fulfilling the unmet health needs of today’s women. Our product and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Our initial product, Twirla®, (levonorgestrel and ethinyl estradiol), a transdermal system, is a non-daily prescription contraceptive. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to allow drug delivery through the skin. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Matt Riley - Head of Investor Relations & Corporate Communications mriley@agiletherapeutics.com Company Website https://agiletherapeutics.com/

October 26, 2022 08:00 AM Eastern Daylight Time

Healthcare